Diabetes mellitus risk in rheumatoid arthritis: Reduced incidence with anti–tumor necrosis factor α therapy
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Objective: To examine the association of tumor necrosis factor α (TNFα) inhibitor use and the risk of developing diabetes mellitus in a rheumatoid arthritis (RA) inception cohort. Methods: Adults diagnosed with RA between January 1, 2001, and December 31, 2009, were identified (n = 1,881). Prevalent cases of diabetes mellitus (n = 294) were excluded. Information on sociodemographic data, medical history, body mass index (BMI), laboratory measures, and medications was collected from the electronic health record. Incident diabetes mellitus was defined using the 2010 American Diabetes Association criteria or physician‐established diagnosis. Time‐varying Cox proportional hazards regression models were used to adjust for age, sex, race, BMI, rheumatoid factor (RF) and anti–cyclic citrullinated peptide antibodies (anti‐CCP), erythrocyte sedimentation rate (ESR), and use of nonsteroidal antiinflammatory drugs (NSAIDs), glucocorticoids, hydroxychloroquine, and methotrexate. Results: A total of 1,587 incident RA patients without diabetes mellitus were included. The anti‐TNFα users (n = 522) had a lower median age but greater baseline BMI; maximum ESR, RF, and anti‐CCP positivity; and NSAID, glucocorticoid, or methotrexate use. The median followup time for the ever and never TNFα inhibitor users was 44.9 months (interquartile range [IQR] 23.7–73.0 months) and 37.1 months (IQR 16.3–65.1 months), respectively (P < 0.001). Of the 91 patients developing diabetes mellitus, 16 were ever and 75 were never TNFα inhibitor users, yielding incidence rates of 8.6 and 17.2 per 1,000 person‐years (P = 0.048), respectively. Adjusting for covariates, the hazard ratio for incident diabetes mellitus in TNFα inhibitor users was 0.49 (95% confidence interval 0.24–0.99, P = 0.049) compared to the never users. Conclusion: In this inception RA cohort, anti‐TNFα use was associated with a 51% reduction in risk of developing diabetes mellitus.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnosis and classification of diabetes mellitus
American Diabetes Association (2010) · Diabetes Care · doi:10.2337/dc10-s062 · Cited by 5,491
Ahima, R. S., & Flier, J. S. (2000) · Annual Review of Physiology · doi:10.1146/annurev.physiol.62.1.413 · Cited by 1,428
Hotamisligil, G. S., Budavari, A., Murray, D., & Spiegelman, B. M. (1994) · Journal of Clinical Investigation · doi:10.1172/jci117495 · Cited by 819
Insulin resistance and impaired beta cell function in rheumatoid arthritis
Dessein, P. H., & Joffe, B. I. (2006) · Arthritis & Rheumatism · doi:10.1002/art.22053 · Cited by 218
Tam, L.-S., Tomlinson, B., Chu, T. T., Li, T. K., & Li, E. K. (2007) · Clinical Rheumatology · doi:10.1007/s10067-007-0539-8 · Cited by 197
Cited by
Inflammation in obesity, diabetes, and related disorders
Rohm, T. V., Meier, D. T., Olefsky, J. M., & Donath, M. Y. (2022) · Immunity · doi:10.1016/j.immuni.2021.12.013 · Cited by 2,066
Targeting inflammation in the treatment of type 2 diabetes: time to start
Donath, M. Y. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4275 · Cited by 690
Cardiovascular disease in autoimmune rheumatic diseases
Hollan, I., Meroni, P. L., Ahearn, J. M., Cohen Tervaert, J. W., Curran, S., Goodyear, C. S., Hestad, K. A., Kahaleh, B., Riggio, M., Shields, K., et al. (2013) · Autoimmunity Reviews · doi:10.1016/j.autrev.2013.03.013 · Cited by 270
Self-citationJohnson, A. R., Qin, Y., Cozzo, A. J., Freemerman, A. J., Huang, M. J., Zhao, L., Sampey, B. P., Milner, J. J., Beck, M. A., Damania, B., et al. (2016) · Molecular Metabolism · doi:10.1016/j.molmet.2016.04.005 · Cited by 130
Burska, A. N., Sakthiswary, R., & Sattar, N. (2015) · PLOS ONE · doi:10.1371/journal.pone.0128889 · Cited by 84
Bili, A., Tang, X., Pranesh, S., Bozaite, R., Morris, S. J., Antohe, J. L., Kirchner, H. L., & Wasko, M. C. M. (2014) · Arthritis Care & Research · doi:10.1002/acr.22166 · Cited by 75
Self-citationInsulin Signaling in Arthritis
Tripolino, C., Ciaffi, J., Pucino, V., Ruscitti, P., van Leeuwen, N., Borghi, C., Giacomelli, R., Meliconi, R., & Ursini, F. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.672519 · Cited by 46
Metadata
- Authors
- Antohe, J. L., Bili, A., Sartorius, J. A., Kirchner, H. L., Morris, S. J., Dancea, S., & Wasko, M. C. M.
- Venue
- Arthritis Care & Research
- Publisher
- Wiley
- Published
- 2012-01-25
- Volume
- 64
- Issue
- 2
- Pages
- 215-221
- ISSN
- 0893-7524 (ISSN-L)
- 2151-464X
- 2151-4658
- OpenAlex
- W2015923223
- Cited by
- 90
- References
- 5
- FWCI
- 3.12
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.